ASIA GOUT DISEASE TREATMENT MARKET ANALYSIS

Market News

Asia Gout Disease Treatment Market: Key Developments

On May 31, 2023, Horizon Therapeutics plc., biotechnology company, announced new analyses from the MIRROR randomized controlled trial of KRYSTEXXA (pegloticase) injection with methotrexate show a multi-faceted impact when treating adults living with chronic gout refractory to oral therapy, or uncontrolled gout.

In December 2022, JW Pharmaceutical, a pharmaceutical companies in Korea, announced through its disclosure on Monday that it had applied last Friday for a phase 3 trial for Epaminurad, a gout treatment, with the Taiwan Food and Drug Authority (TFDA).

In August 2020, Teijin Pharma Limited, a developing business in the field of pharmaceuticals and home healthcare equipments, and Astellas Pharma Inc., a multinational pharmaceutical company in Japan, announced that they have entered into an exclusive distribution agreement for febuxostat, a novel drug for the treatment of gout and hyperuricemia, in Southeast Asia and India.

In April 2022, Specialty Networks, LLC, a portfolio company of Linden Capital Partners is an integrated, multi-specialty organization with GPOs, Life Sciences, and Research solutions in U.S., announced the acquisition of United Rheumatology, LLC is the Rheumatology group purchasing organization (GPO) and real-world evidence (RWE) data & analytics company, community Rheumatology clinics will be able to maintain their independence while also improving the standard of treatment for patients.

In May 2021, the Arthritis Foundation, the nonprofit organization dedicated to the prevention control and cure of America\'s leading cause of rheumatoid arthritis, announced the launch of a application (Vim, the Arthritis Foundation\'s mobile app) and kicks off Arthritis Awareness with the release of key findings from a patient study.

In May 2022, United Rheumatology, the rheumatology care management organization empowering rheumatologists to advance the standard of care, and CreakyJoints, a support, education, advocacy, and research organization for people living with arthritis and rheumatic disease, announced a partnership to develop the Rheumatoid Arthritis Wellness Center, a digital resource aimed at aiding those living with rheumatoid arthritis.

In September 2021, Labcorp, a life sciences company based in the U.S., announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra rheumatoid arthritis (RA) assay.